Tel Aviv, Israel, September 13, 2022 /PRNewswire/ — Microtech, a wholly owned subsidiary of Medinol, Inc., a global MedTech research and development leader, has announced that its implantable microsensor platform Cardiovascular Research Foundation Annual Scientific Symposium 34th Transcatheter Cardiovascular Treatment (TCT) A prestigious selection, this session will focus on a limited number of state-of-the-art technologies important to the advancement of cardiovascular care. Microtech is honored that he was selected as one of the participating organizations.
The Microtech Implantable Microsensor Platform builds on decades of development in a new class of sensor technology that can be used as a stand-alone device as well as integrated into existing devices, transforming them from therapeutic-only to smart data-gathering devices. It’s a culmination. You can perform multiple functions at once.
session entitled “Microsensors: Turning implantable devices into real-time physiological monitors (Microtech)” We present a procedure demonstrating a device incorporating the Microtech implantable microsensor platform implanted in the left atrium for ongoing assessment of heart failure. In addition to the case presentation, Dr. Yoram Richter Ph.D., CEO of Medinol Ltd, will present the technology platform, followed by his Q/A and roundtable discussion with the invited panel.
“By adding sensors to existing medical devices, physicians will be able to treat patients based on quantifiable physiological parameters rather than symptoms, expanding access to equitable healthcare across the global community. The platform can provide highly accurate pressure readings immediately and directly to the physician, regardless of geographic distance or travel issues.” Joram Richter“Microtech’s implantable microsensor platform can be used for a variety of scenarios including patients with heart failure, glaucoma, hydrocephalus, portal hypertension, AAA endoleaks, etc., so we are excited about the integration, adoption and adoption of this innovative platform. Implantation expands access to healthcare and reduces patient visits to office/hospital visits. to the lifelong care of the patient.”
About Medinol
Medinol is actively changing the paradigm of how disease states are diagnosed and treated. Whether designing state-of-the-art devices to place stents in multiple regions of the body, dramatically reducing the complexity of structural heart surgery, or real-time physiological metrics of the human body via implantable sensors. We are boldly reassessing current techniques and procedures and looking several years ahead, whether it’s an insight into the future. Pioneer new devices to expand the reach of physicians physically and geographically. Medinol works with physicians and industry partners to create the future today.
For more information, please visit www.medinol.com or contact us. Jeff RoachChief Commercial Officer at JeffR@medinol.com.
Logo – https://mma.prnewswire.com/media/1895526/Medinol_Logo.jpg
SOURCE Medinol
Comments
Post a Comment